• News
    • News
    • Upcoming Events
    • Subscribe
  • Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Alzinova Team
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Press Releases
      • English
      • Swedish
      • Subscribe
    • Presentations
    • Company Presesentation
    • The Share
      • Share Information
      • Largest Shareholders
      • Share Capital Development
      • Rights Issues / Företrädesemissioner
      • Previous Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Nomination Committee / Valberedning
      • Articles of Association
      • Auditor
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
  • Career
  • Contact
logo
  • News
    • News
    • Upcoming Events
    • Subscribe
  • Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Alzinova Team
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Press Releases
      • English
      • Swedish
      • Subscribe
    • Presentations
    • Company Presesentation
    • The Share
      • Share Information
      • Largest Shareholders
      • Share Capital Development
      • Rights Issues / Företrädesemissioner
      • Previous Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Nomination Committee / Valberedning
      • Articles of Association
      • Auditor
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
  • Career
  • Contact
Home / Investors / The Share / Analyst Coverage
  • Overview
  • Press Releases
    • English
    • Swedish
    • Subscribe
  • Presentations
  • Company Presentation
  • The Share
    • Share Information
    • Largest Shareholders
    • Share Capital Development
    • Rights Issues / Företrädesemissioner
    • Analyst Coverage
  • Financial Reports
    • English
    • Swedish
  • Financial Calendar
  • Corporate Governance
    • General Meetings
    • Nomination Committee / Valberedning
    • Previous Nomination Committees
    • Auditor
    • Articles of Association
    • Board of Directors
    • Management
  • Certified Adviser
  • IR Contact

Analyst Coverage

 

Redeye Equity Research
Kevin Sule, Analyst
Phone: +46 720 92 18 87
E-mail: kevin.sule@redeye.se

Company site at Redeye

Analysis February 2023. View pdf

Analysis June 2022. View  pdf

Analysis November 2021. View pdf

Analysis January 2019. View pdf

 

Additional Equity Research by Mangold

Analysis 22 March 2023. View pdf

Analysis 12 October 2022. View pdf

Analysis 2 June 2022. View pdf

Analysis 26 January 2022. View pdf

 

Additional Equity Research by Carlsquare

Analysis in Swedish 

  • News
  • Our Company
  • Patients & Families
  • R & D
  • Investors
  • Contact

Alzinova AB. Pepparedsleden 1, SE-431 83, Mölndal, Sweden
+46 (0) 708 467 975   info@alzinova.com

Follow us on

follow us on linkedin